DK3211082T3 - Mikrorna-forbindelser og fremgangsmåder til modulering af mir-21-aktivitet - Google Patents

Mikrorna-forbindelser og fremgangsmåder til modulering af mir-21-aktivitet Download PDF

Info

Publication number
DK3211082T3
DK3211082T3 DK17153724.4T DK17153724T DK3211082T3 DK 3211082 T3 DK3211082 T3 DK 3211082T3 DK 17153724 T DK17153724 T DK 17153724T DK 3211082 T3 DK3211082 T3 DK 3211082T3
Authority
DK
Denmark
Prior art keywords
microrna
connections
activity
methods
modulating mir
Prior art date
Application number
DK17153724.4T
Other languages
English (en)
Inventor
Balkrishen Bhat
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Application granted granted Critical
Publication of DK3211082T3 publication Critical patent/DK3211082T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/343—Spatial arrangement of the modifications having patterns, e.g. ==--==--==--
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
DK17153724.4T 2011-04-25 2012-04-25 Mikrorna-forbindelser og fremgangsmåder til modulering af mir-21-aktivitet DK3211082T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161478767P 2011-04-25 2011-04-25
US201161565779P 2011-12-01 2011-12-01
EP12718549.4A EP2702155B9 (en) 2011-04-25 2012-04-25 Microrna compounds and methods for modulating mir-21 activity

Publications (1)

Publication Number Publication Date
DK3211082T3 true DK3211082T3 (da) 2021-05-10

Family

ID=46025979

Family Applications (2)

Application Number Title Priority Date Filing Date
DK12718549.4T DK2702155T3 (da) 2011-04-25 2012-04-25 Mikro-rna-forbindelser og fremgangsmåder til modulering af mir-21-aktivitet
DK17153724.4T DK3211082T3 (da) 2011-04-25 2012-04-25 Mikrorna-forbindelser og fremgangsmåder til modulering af mir-21-aktivitet

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK12718549.4T DK2702155T3 (da) 2011-04-25 2012-04-25 Mikro-rna-forbindelser og fremgangsmåder til modulering af mir-21-aktivitet

Country Status (30)

Country Link
US (7) US20120270928A1 (da)
EP (3) EP2702155B9 (da)
JP (2) JP6320292B2 (da)
KR (2) KR20190063482A (da)
CN (3) CN103620035B (da)
AU (4) AU2012249851B2 (da)
BR (1) BR112013027187A2 (da)
CA (2) CA2833615C (da)
CL (1) CL2013003105A1 (da)
CO (1) CO6821889A2 (da)
CY (1) CY1120304T1 (da)
DK (2) DK2702155T3 (da)
EA (1) EA025894B1 (da)
ES (2) ES2621863T3 (da)
HK (1) HK1243130A1 (da)
HR (2) HRP20170557T2 (da)
HU (2) HUE054129T2 (da)
IL (3) IL229032B (da)
LT (2) LT2702155T (da)
MX (5) MX2013012452A (da)
MY (2) MY175336A (da)
NZ (1) NZ717921A (da)
PL (2) PL2702155T3 (da)
PT (2) PT3211082T (da)
RS (1) RS61775B1 (da)
SG (1) SG194636A1 (da)
SI (2) SI3211082T1 (da)
TW (2) TWI698445B (da)
UA (1) UA115652C2 (da)
WO (1) WO2012148952A1 (da)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8173611B2 (en) 2004-11-12 2012-05-08 Asuragen Inc. Methods and compositions involving miRNA and miRNA inhibitor molecules
TWI698445B (zh) * 2011-04-25 2020-07-11 法商賽諾菲公司 微型ｒｎａ化合物及調控ｍｉｒ－２１活性之方法
WO2013153082A1 (en) * 2012-04-10 2013-10-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of nonalcoholic steatohepatitis
JP6322189B2 (ja) 2012-04-25 2018-05-09 レグルス セラピューティクス インコーポレイテッド Ｍｉｒ−２１活性を調節するためのマイクロｒｎａ化合物及び方法
UA116639C2 (uk) 2012-10-09 2018-04-25 Рег'Юлес Терап'Ютікс Інк. Способи лікування синдрому альпорта
JP2016503300A (ja) 2012-11-15 2016-02-04 ロシュ・イノベーション・センター・コペンハーゲン・アクティーゼルスカブＲｏｃｈｅ Ｉｎｎｏｖａｔｉｏｎ Ｃｅｎｔｅｒ Ｃｏｐｅｎｈａｇｅｎ Ａ／Ｓ 抗ＡｐｏＢアンチセンス複合体化合物
AU2014259954B2 (en) * 2013-05-01 2019-11-07 Regulus Therapeutics Inc. MicroRNA compounds and methods for modulating miR-122
EP3060664B1 (en) 2013-10-25 2021-07-07 Sanofi Microrna compounds and methods for modulating mir-21 activity
KR101625755B1 (ko) 2013-11-18 2016-05-30 울산대학교 산학협력단 ｍｉＲＮＡ 스폰지 및 이의 용도
JP2017505623A (ja) * 2014-01-30 2017-02-23 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 生物切断性コンジュゲートを有するポリオリゴマー化合物
CN105734127A (zh) * 2016-02-29 2016-07-06 上海中医药大学 miR-21-3p在制备用于检测早期急性肾损伤的试剂中的用途
WO2017187426A1 (en) * 2016-04-29 2017-11-02 Aptamir Therapeutics, Inc. Inhibition of mir-22 mirna by apt-110
EP4035659A1 (en) 2016-11-29 2022-08-03 PureTech LYT, Inc. Exosomes for delivery of therapeutic agents
CN111386351A (zh) 2017-09-22 2020-07-07 华盛顿大学 细胞分子的原位组合标记
CN108148911B (zh) * 2018-03-02 2019-11-05 广州医科大学附属第二医院 miR-582在制备前列腺癌骨转移的诊断、预后试剂盒及药物中的应用
JP7279081B2 (ja) 2018-05-08 2023-05-22 レグルス セラピューティクス インコーポレイテッド Ｍｉｒ－１２２を調節するためのマイクロｒｎａ化合物及び方法
CN110747266A (zh) * 2018-07-23 2020-02-04 深圳先进技术研究院 miR-21和miR-21拮抗剂在抑制预防/治疗1型糖尿病中的应用
CN109880907A (zh) * 2019-03-26 2019-06-14 中国人民解放军第八一医院 一种肝癌细胞侵袭转移的分子机制研究方法
US11965162B2 (en) 2020-04-16 2024-04-23 The Johns Hopkins University MicroRNA and inhibitors thereof and methods of treatment
WO2022165092A1 (en) * 2021-01-29 2022-08-04 Angion Biomedica Corp. Methods for treatment of fibrotic diseases

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060008817A1 (en) * 2000-12-08 2006-01-12 Invitrogen Corporation Methods and compositions for generating recombinant nucleic acid molecules
EP2385123B1 (en) 2001-09-28 2018-04-25 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Microrna molecules
WO2004041889A2 (en) 2002-11-05 2004-05-21 Isis Pharmaceuticals, Inc. Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
US7683036B2 (en) 2003-07-31 2010-03-23 Regulus Therapeutics Inc. Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
ATE555118T1 (de) 2003-08-28 2012-05-15 Takeshi Imanishi Neue synthetische nukleidsäuren vom typ mit quervernetzter n-o-bindung
EP1791567B1 (en) 2004-08-10 2015-07-29 Alnylam Pharmaceuticals Inc. Chemically modified oligonucleotides
US8173611B2 (en) 2004-11-12 2012-05-08 Asuragen Inc. Methods and compositions involving miRNA and miRNA inhibitor molecules
EP1959012A3 (en) 2004-12-29 2009-12-30 Exiqon A/S Novel oligonucleotide compositions and probe sequences useful for detection and analysis of microRNAs and their target mRNAs
US6995235B1 (en) 2005-05-02 2006-02-07 Univation Technologies, Llc Methods of producing polyolefins and films therefrom
DK1931780T3 (da) 2005-08-29 2016-01-25 Regulus Therapeutics Inc Antisense-forbindelser med forøget anti-microrna-aktivitet
JP5342881B2 (ja) 2006-01-27 2013-11-13 アイシス ファーマシューティカルズ， インコーポレーテッド ６−修飾された二環式核酸類似体
JP5213723B2 (ja) 2006-01-27 2013-06-19 アイシス ファーマシューティカルズ， インコーポレーテッド マイクロｒｎａの調節に使用するためのオリゴマー化合物及び組成物
WO2007112754A2 (en) 2006-04-03 2007-10-11 Santaris Pharma A/S Pharmaceutical compositions comprising anti-mirna antisense oligonucleotides
EP3502255A1 (en) * 2006-04-03 2019-06-26 Roche Innovation Center Copenhagen A/S Pharmaceutical composition
AU2007303205A1 (en) 2006-10-03 2008-04-10 Tekmira Pharmaceuticals Corporation Lipid containing formulations
EP2094869B1 (de) 2006-10-09 2012-07-25 Julius-Maximilians-Universität Würzburg Microrna (mirna) zur diagnose und therapie von herzerkrankungen
AU2007333107A1 (en) 2006-12-08 2008-06-19 Asuragen, Inc. miR-21 regulated genes and pathways as targets for therapeutic intervention
US8048998B2 (en) 2007-01-19 2011-11-01 Exiqon A/S Mediated cellular delivery of LNA oligonucleotides
US8278425B2 (en) 2007-05-30 2012-10-02 Isis Pharmaceuticals, Inc. N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
EP2173760B2 (en) 2007-06-08 2015-11-04 Isis Pharmaceuticals, Inc. Carbocyclic bicyclic nucleic acid analogs
WO2008151631A2 (en) 2007-06-15 2008-12-18 Exiqon A/S Use of short oligonucleotides for reagent redundancy experiments in rna functional analysis
CN101796062B (zh) 2007-07-05 2014-07-30 Isis制药公司 6-双取代双环核酸类似物
US8440637B2 (en) * 2007-10-04 2013-05-14 Santaris Pharma A/S Combination treatment for the treatment of hepatitis C virus infection
CN101980712B (zh) 2007-10-29 2015-02-18 雷古拉斯治疗公司 用于肝癌治疗的靶向微小rna
US20110257244A1 (en) 2008-01-18 2011-10-20 Alnylam Pharmaceuticals, Inc. Chemically modified oligonucleotides and small molecules for use in reducing micro rna activity levels and uses thereof
EP2096171A1 (en) 2008-02-27 2009-09-02 Julius-Maximilians-Universität Würzburg MicroRNA (miRNA) and down-stream targets for diagnostic and therapeutic purposes
CA2717792A1 (en) 2008-03-07 2009-09-11 Santaris Pharma A/S Pharmaceutical compositions for treatment of microrna related diseases
WO2010099161A1 (en) * 2009-02-26 2010-09-02 The Ohio State University Research Foundation Micrornas in never-smokers and related materials and methods
AU2010258875A1 (en) * 2009-06-08 2012-01-19 Miragen Therapeutics Chemical modification motifs for miRNA inhibitors and mimetics
WO2011126842A2 (en) 2010-03-30 2011-10-13 Regulus Therapeutics Inc. Targeting micrornas for the treatment of cardiac disorders
TWI698445B (zh) 2011-04-25 2020-07-11 法商賽諾菲公司 微型ｒｎａ化合物及調控ｍｉｒ－２１活性之方法
WO2013013165A2 (en) 2011-07-21 2013-01-24 The Trustees Of The University Of Pennsylvania Use of lna compounds for therapeutic inhibition of mir-21 in systemic lupus erythematosus
JP6322189B2 (ja) 2012-04-25 2018-05-09 レグルス セラピューティクス インコーポレイテッド Ｍｉｒ−２１活性を調節するためのマイクロｒｎａ化合物及び方法
CA2876180C (en) 2012-06-21 2019-11-19 MiRagen Therapeutics, Inc. Oligonucleotide-based inhibitors comprising locked nucleic acid motif
JP6352269B2 (ja) 2012-09-26 2018-07-04 ミルクス セラピューティクス アクティーゼルスカブＭｉｒｒｘ Ｔｈｅｒａｐｅｕｔｉｃｓ Ａ／Ｓ オフターゲットプロファイルの改善されたオリゴマー
UA116639C2 (uk) 2012-10-09 2018-04-25 Рег'Юлес Терап'Ютікс Інк. Способи лікування синдрому альпорта

Also Published As

Publication number Publication date
UA115652C2 (uk) 2017-12-11
CA2833615C (en) 2022-08-30
MX2022006595A (es) 2022-07-01
WO2012148952A1 (en) 2012-11-01
KR102055172B1 (ko) 2020-01-23
EP2702155B9 (en) 2020-01-01
US9790496B2 (en) 2017-10-17
US20180155719A1 (en) 2018-06-07
SI2702155T1 (sl) 2017-07-31
CA2833615A1 (en) 2012-11-01
US20120270928A1 (en) 2012-10-25
EA025894B1 (ru) 2017-02-28
AU2012249851A8 (en) 2013-11-14
AU2017219156A1 (en) 2017-09-21
US20140107183A1 (en) 2014-04-17
AU2017219156B2 (en) 2020-01-02
CO6821889A2 (es) 2013-12-31
IL273381A (en) 2020-05-31
CA3165397A1 (en) 2012-11-01
IL229032A0 (en) 2013-12-31
KR20190063482A (ko) 2019-06-07
PT2702155T (pt) 2017-04-03
TW201811812A (zh) 2018-04-01
JP2018121646A (ja) 2018-08-09
CN103620035A (zh) 2014-03-05
NZ717921A (en) 2017-09-29
AU2022203067A1 (en) 2022-05-26
HK1243130A1 (zh) 2018-07-06
US20200291400A1 (en) 2020-09-17
EA201391492A1 (ru) 2014-04-30
ES2621863T3 (es) 2017-07-05
EP2702155B1 (en) 2017-02-01
IL229032B (en) 2021-01-31
US20140329887A1 (en) 2014-11-06
EP3933040A1 (en) 2022-01-05
CN113249381A (zh) 2021-08-13
NZ616748A (en) 2016-03-31
MX2022000212A (es) 2022-04-01
EP3211082B1 (en) 2021-02-17
CN113151272A (zh) 2021-07-23
MX2019003090A (es) 2019-07-18
US9181547B2 (en) 2015-11-10
TW201300404A (zh) 2013-01-01
KR20140033062A (ko) 2014-03-17
MY175336A (en) 2020-06-19
PL3211082T3 (pl) 2021-08-02
PL2702155T3 (pl) 2017-09-29
MY187685A (en) 2021-10-11
CY1120304T1 (el) 2019-07-10
DK2702155T3 (da) 2017-05-01
US20220098583A1 (en) 2022-03-31
SG194636A1 (en) 2013-12-30
PT3211082T (pt) 2021-04-28
CL2013003105A1 (es) 2014-08-01
BR112013027187A2 (pt) 2017-06-06
CN103620035B (zh) 2021-04-23
IL266529A (en) 2019-07-31
TWI607016B (zh) 2017-12-01
MX2013012452A (es) 2014-11-21
HUE031595T2 (en) 2017-07-28
HRP20170557T1 (hr) 2017-06-16
ES2621863T9 (es) 2020-02-13
HRP20210616T1 (hr) 2021-05-28
LT3211082T (lt) 2021-05-10
AU2012249851A1 (en) 2013-10-31
LT2702155T (lt) 2017-05-10
JP2014518619A (ja) 2014-08-07
EP2702155A1 (en) 2014-03-05
TWI698445B (zh) 2020-07-11
SI3211082T1 (sl) 2021-08-31
JP6320292B2 (ja) 2018-05-09
HRP20170557T2 (hr) 2020-02-21
US20160138016A1 (en) 2016-05-19
US8912161B2 (en) 2014-12-16
HUE054129T2 (hu) 2021-08-30
AU2020201403A1 (en) 2020-03-12
ES2868950T3 (es) 2021-10-22
EP3211082A1 (en) 2017-08-30
MX2019003089A (es) 2019-07-18
RS61775B1 (sr) 2021-05-31
AU2012249851B2 (en) 2017-06-08

Similar Documents

Publication Publication Date Title
DK3211082T3 (da) Mikrorna-forbindelser og fremgangsmåder til modulering af mir-21-aktivitet
HK1207115A1 (en) Microrna compounds and methods for modulating mir-21 activity mir-21 rna
DK2906696T3 (da) Fremgangsmåder til modulering af c9orf72-ekspression
DK2890780T3 (da) Fremgangsmåder og sammensætninger til behandling af en genetisk tilstand
DK3468197T3 (da) Fremgangsmåde til interforudsigelse og indretning dertil
DK2709613T4 (da) Fremgangsmåder til behandling af hcv
HK1221256A1 (zh) 用於調節 的微小 化合物和方法
BR112013024167A2 (pt) espaçador intercorporal expansível
DK2788958T3 (da) Fremgangsmåde og system til at karakterisere plantefænotype
DK2553113T3 (da) FREMGANGSMÅDE TIL FREMSTILLING AF L-ORNITHIN UNDER ANVENDELSE AF LysE-OVEREKSPRIMERENDE BAKTERIER
DK2625253T3 (da) System og fremgangsmåde til ristning af biomasse
DK2758172T3 (da) System til udførelse af reaktioner
DK2758655T3 (da) Systemer og fremgangsmåder til forbedrede vandrotorer
DK2665486T3 (da) Sammensætninger til modulering af gamma-c-cytokin-aktivitet
DK2861711T3 (da) Engangsbioreaktor og hovedplade, og en fremgangsmåde til fremstilling deraf
DK2855500T3 (da) Fremgangsmåder og sammensætninger til modulering af apolipoprotein (A)-ekspression
DK2785683T3 (da) Inkt-cellemodulatorer og fremgangsmåder til anvendelse heraf
DK2719005T3 (da) Fremgangsmåde og system til genindvinding af bestanddele af batterier
DK3575792T3 (da) Fremgangsmåde til vurdering af risiko for pml
BR112014029365A2 (pt) inibidores seletivos de células indiferenciadas
DK2541503T3 (da) Fremgangsmåde og system til måling af RF-forbindelsesmargin
DK2808346T3 (da) Fremgangsmåde til fremstilling af tørret biocellulose
DK2633029T3 (da) Sammensætninger og fremgangsmåder til dyrkning af spirokæter
DK2739565T3 (da) Fremgangsmåde til fremstilling af partikelklynger
DK2796406T3 (da) Indretning til forskydningsomdannelse af co og fremgangsmåde til forskydningsomdannelse